Healthcare
Neuren Pharmaceuticals Limited(NURPF)
Live Price
Offline$8.88
+0.00% today
1Y Change
-1.36%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $1.58B
- Revenue Growth
- -70.2%
- EPS Growth
- -78.0%
- Dividend Yield
- 0.0%
Coverage: 252 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Neuren Pharmaceuticals Limited (NURPF) is a Healthcare stock with a market cap of $1.58B and listed on OTC. The stock last traded around $8.88 and down 1.4% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -70.2%, EPS growth of -78.0%, a dividend yield of 0.0%. What stands out right now is revenue -70.2%, EPS -78.0%, free cash flow +1211.1% with operating margin 11.0% and ROIC 1.6%. Valuation already assumes a fairly strong business story at P/E 51.9 and price/sales 24.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines NURPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-70.2% vs +7.6% peer median
Operating Margin
Below sector median
+11.0% vs +19.4% peer median
P/E
Above sector median
51.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Feb 25, 2026 with an EPS surprise of +776.8% and a revenue surprise of +1.0%.
The operating picture looks softer than before
Revenue is at -70.2% and EPS is at -78.0%, with operating margin around 11.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 25, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 25, 2026 | +776.8% | +0.0% | +0.0% | -3.6% |
2025 Aug 26, 2025 | -0.3% | +0.0% | +16.1% | -0.4% |
2025 Feb 27, 2025 | -0.9% | +0.0% | +0.0% | +24.9% |
Benchmark Edge
NURPF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NURPF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NURPF Max Drawdown
-44.45%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NURPF and SPY.
Company Overview
Neuren Pharmaceuticals Limited
Other OTC
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
- Leadership
- Jonathan Charles Pilcher
- IPO Date
- Nov 4, 2009
- Employees
- 8
- Street Address
- 697 Burke Road
- Mailing
- Camberwell, VIC, 3124
- Region
- Camberwell, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 9092 0480
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 51.9
- EV/EBITDA
- 71.4
- Price/Sales
- 24.4
- Price/Book
- 4.7
Growth
- Revenue
- -70.2%
- EPS
- -78.0%
- Free Cash Flow
- +1211.1%
Profitability
- Gross Margin
- 76.9%
- Operating Margin
- 11.0%
- Net Margin
- 47.1%
- ROE
- 9.2%
- ROIC
- 1.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 76.60
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.